DOCSLIB.ORG

Monthly Healthcare Review June 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Monthly Healthcare Review June 2017 Monthly Healthcare Review June 2017 IPOs The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month. Last Last Financing Financing Company Name HQ Location Description Lead Manager Date Size (Millions) Developer of myoelectric prosthetic technology designed to offer expanded mobility for Myomo (MYO) 9-Jun-17 Cambridge, MA those suffering from neurological disorders and upper-limb paralysis. 7.90 Undisclosed Bank of America Merrill Lynch, China Merchants Shanghai, Provider of a highly customizable range of services for the discovery, development, and Securities, Morgan Wuxi Biologics (02269) 13-Jun-17 China manufacturing of biologics. 510.54 Stanley Credit Suisse Securities, Deutche Bank Securities, J.P. Athenex (ATNX) 14-Jun-17 Buffalo, NY Developer of novel therapies created to treat cancer and immunomodulatory diseases. 66.00 Morgan Securities Surgical Science Göteborg, Developer of virtual reality simulators designed for medical training in the laparoscopic and Sweden (SUS) 19-Jun-17 Sweden endoscopic fields. 7.97 Undisclosed Imagion Biosystems Albuquerque, Developer of a technology that uses magnetic nanoparticles combined with antibodies and Focus Capital (IBX) 22-Jun-17 NM targets specific kinds of cancer cells. 8.92 Group Cowen and Company, J.P. Developer of an antibody drug conjugate cancer therapy created to precisely target highly Morgan Securities. Mersana Therapeutics 27-Jun-17 Cambridge, MA tailored drugs. 75.00 Leerink Partners Oppenheimer & Co., Raymond Avenue Therapeutics James and (ATXI) 27-Jun-17 New York, NY Developer of specialty pharmaceutical products focused on post-operative pain treatment. 33.00 Associates Axis Capital Limited, Citigroup Global Markets, Eris Lifesciences Ahmedabad, Manufacturer and distributor of pharmaceuticals focused on cardiovascular, diabetes, Credit Suisse (540596) 29-Jun-17 India gastroenterology and orthopedic segments. 270.32 Securities Source: Pitchbook Compiled By: Lea Keller and Morgan Reape 1 Monthly Healthcare Review June 2017 IPOs The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month. Last Last Financing Financing Company Name HQ Location Description Lead Manager Date Size (Millions) Bank of America Aileron Therapeutics Developer of a proprietary peptide technology platform to generate therapeutics for the Merrill Lynch, (ALRN) 29-Jun-17 Cambridge, MA treatment of cancer. 156.25 Jefferies J.P Morgan Dova Pharmaceuticals Charlottesville, Developer of investigational compounds for the treatment of thrombocytopenia in patients Securities, Jefferies, (DOVA) 30-Jun-17 VA with chronic liver disease undergoing an elective procedure. 75.06 Leerink Partners Source: Pitchbook Compiled By: Lea Keller and Morgan Reape 2 Monthly Healthcare Review June 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions) Developer of a SaaS-based medical billing platform designed to provide automation technologies for medical groups, medical billing companies, PE Growth/ and PM/EMR vendors to transact directly with the major payers and Encoda 1-Jun-17 Tampa, FL Expansion eliminate the need for a clearinghouse. 1.50 Clearwell Group FCA Venture Partners, Developer of a health plan search platform for compliance and risk Undisclosed Vericred 1-Jun-17 New York, NY Early Stage VC management driven credentialing functions. 5.53 Investors Greenspring Associates, Greycroft Partners, Redpoint Ventures, Cross Creek Advisors, New Enterprise Associates, Provider of a health insurance service platform that partners with health Bessemer Venture systems to provide health plans and support relationships between Partners, Flare Bright Health 1-Jun-17 Minneapolis, MN Early Stage VC consumers and care providers. 160.00 Capital Partners HenQ, Northzone, Health Innovations, Amsterdam, Developer of artificial intelligence-based imaging software used for faster Undisclosed Aidence 1-Jun-17 Netherlands Seed Round diagnosing of X-ray, MRI, and CT images. 2.48 Investors Accelerator/ Developer of a urine testing device designed to monitor infections in urine StreamSense Medical 1-Jun-17 Charlottesville, VA Incubator samples at home. 0.01 i.Lab at UVA Developer of a viral DNA/RNA detection device designed for the point Infinity Capital, AltraTech 1-Jun-17 Limerick, Ireland Early Stage VC of care testing of infectious viral diseases. 2.43 Kernel Capital Source: Pitchbook Compiled By: Lea Keller and Morgan Reape 3 Monthly Healthcare Review June 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions) James W. Bullock, William A. Hawkins, Provider of detection instruments for cardiac diseases, such as atrial Piedmont Capital fibrillation detection, to deliver targeted therapies to affected areas within Partners, Solas CardioNXT 1-Jun-17 Westminster, CO Early Stage VC the heart. 2.10 Bioventures Operator of a biotechnology company intended to develop therapeutic vaccines for the treatment of autoimmune and inflammatory diseases Neovacs (ALNEV) 1-Jun-17 Paris, France PIPE using its proprietary Kinoid technology. 4.09 Kepler Cheuvreux Developer and manufacturer of neurosurgical instruments made of Undisclosed Kogent Surgical 1-Jun-17 Chesterfield, MO Later Stage VC lightweight, non-magnetic titanium. 0.05 Investors Developer of medical devices that utilize micro-sensors, wireless technologies, and custom software applications, designed to improve Undisclosed ArthroMeda 1-Jun-17 Lowell, MA Later Stage VC surgical outcomes for patients undergoing joint replacement procedures. 1.50 Investors Versant Ventures, SightLine Partners, Birchview Capital, BDC Capital's Developer of MRI-guided, laser-based systems for the ablation of brain Healthcare Venture Monteris Medical 1-Jun-17 Plymouth, MN Later Stage VC lesions. 26.58 Fund Vertex Ventures HC, Cambridge Innovation Capital, Developer of bicyclic peptides that combine antibody-like affinity and Longwood Fund, selectivity with small molecule-like tissue penetration, tuneable exposure, Novartis Venture flexible pharmacokinetics, and chemical synthesis, exploring the potential Fund, SROne, SV Cambridge, United of bicyclic peptides as targeted, titratable, and rapidly penetrant Health Investors, Bicycle Therapeutics 1-Jun-17 Kingdom Later Stage VC immunomodulators. 51.71 Atlas Venture Source: Pitchbook Compiled By: Lea Keller and Morgan Reape 4 Monthly Healthcare Review June 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions) Siparex Group, Edmond de Rothschild Investment Partners, Secondary CM-CIC Beuvry-la-Forêt, Transaction - Manufacturer of fine chemicals, pharmaceutical intermediates, and active Investissement, Minakem 1-Jun-17 France Private pharmaceutical ingredients. Undisclosed Groupe IRD Aktia Kapitalförvaltning, Evli Group, Fondbolaget Fondita, Ilmarinen Mutual Pension Insurance Company, Op Asset Detection Technology Designer, manufacturer, and distributor of X-ray detectors and related Management, Sp- (Finland) (DETEC) 1-Jun-17 Oulu, Finland PIPE control systems. Undisclosed Rahastoyhtiö Developer of cancer immunotherapies designed to recognize and destroy tumor cells by activating an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor's ability to mute the immune response, F-Prime Capital Checkmate enabling cancer patients with advanced cutaneous melanoma to begin Partners, Sofinnova Pharmaceuticals 2-Jun-17 Cambridge, MA Early Stage VC treatment successfully. 27.00 Ventures, venBio Operator of a bio pharma company developing microbiome modulating therapeutics and commercializing small molecule formulations and dietary Accelerator/ fibers that modulate the gut microbiome to confer protection against food New Venture ClostraBio 2-Jun-17 Chicago, IL Incubator antigens. 0.04 Challenge Source: Pitchbook Compiled By: Lea Keller and Morgan Reape 5 Monthly Healthcare Review June 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Investor(s) Size Date (Millions) Novartis Venture Funds, Novo, Developer of therapeutics against genetic targets for neurodegenerative Undisclosed E-scape Bio 2-Jun-17 San Francisco, CA Early Stage VC diseases, including Alzheimer's Disease and Lewy Body Disease. 46.00 Investors Provider
Load more

Recommended publications
  • Philadelphia Investment Trends Report
    Venture impact Technology investment in the Greater Philadelphia region Trends and highlights, January 2008 to June 2013 Innovation, investment and opportunity On behalf of EY, Ben Franklin Technology Partners of Southeastern Pennsylvania and the Greater Philadelphia Alliance for Capital and Technologies (PACT), we are pleased to present this review 421 companies of technology investment trends and highlights in the Greater Philadelphia region. $4.1 billion The technology investment community in the Greater Philadelphia region includes a wide variety of funding sources supporting a diverse array of companies and industry sectors. In this report, Total investment since we’ve analyzed more than a thousand investment rounds and January 2008 exits that occurred in the Philadelphia region since 2008 – including investments from venture capital fi rms (VCs), angel investors (Angels), corporate/strategic investors, seed funds, accelerators and other sources of funding. As shown in this report, 2012 reversed a post-recession slowdown in venture funding in Greater Philadelphia, and to date, 2013 has brought a welcome increase in the amount of new funds available at regional investment fi rms. These are positive signs for our region’s technology companies, as are the increasing number of exits via IPO and acquisition, which serve as further validation of the investment opportunities created by our region’s growing technology sector. We encourage you to explore this report, and we hope that it will provide useful insights into the current state of
    [Show full text]
  • Vol. 84 Wednesday, No. 171 September 4, 2019 Pages 46419
    Vol. 84 Wednesday, No. 171 September 4, 2019 Pages 46419–46652 OFFICE OF THE FEDERAL REGISTER VerDate Sep 11 2014 20:59 Sep 03, 2019 Jkt 247001 PO 00000 Frm 00001 Fmt 4710 Sfmt 4710 E:\FR\FM\04SEWS.LOC 04SEWS jbell on DSK3GLQ082PROD with FRONTWS II Federal Register / Vol. 84, No. 171 / Wednesday, September 4, 2019 The FEDERAL REGISTER (ISSN 0097–6326) is published daily, SUBSCRIPTIONS AND COPIES Monday through Friday, except official holidays, by the Office PUBLIC of the Federal Register, National Archives and Records Administration, under the Federal Register Act (44 U.S.C. Ch. 15) Subscriptions: and the regulations of the Administrative Committee of the Federal Paper or fiche 202–512–1800 Register (1 CFR Ch. I). The Superintendent of Documents, U.S. Assistance with public subscriptions 202–512–1806 Government Publishing Office, is the exclusive distributor of the official edition. Periodicals postage is paid at Washington, DC. General online information 202–512–1530; 1–888–293–6498 Single copies/back copies: The FEDERAL REGISTER provides a uniform system for making available to the public regulations and legal notices issued by Paper or fiche 202–512–1800 Federal agencies. These include Presidential proclamations and Assistance with public single copies 1–866–512–1800 Executive Orders, Federal agency documents having general (Toll-Free) applicability and legal effect, documents required to be published FEDERAL AGENCIES by act of Congress, and other Federal agency documents of public Subscriptions: interest. Assistance with Federal agency subscriptions: Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the Email [email protected] issuing agency requests earlier filing.
    [Show full text]
  • RESI Boston Program Guide 09-26-2017 Digital
    SEPTEMBER 26 , 2017 BOSTON, MA Early stage investors, fundraising CEOs, scientist-entrepreneurs, strategic partners, and service providers now have an opportunity to Make a Compelling Connection ONSITE GUIDE LIFE SCIENCE NATION Connecting Products, Services & Capital #RESIBOS17 | RESIConference.com | Boston Marriott Copley Place FLOOR PLAN Therapeutics Track 2 Investor Track 3 & track4 Track 1 Device, Panels Workshops & Diagnostic & HCIT Asia Investor Panels Panels Ad-Hoc Meeting Area Breakfast & Lunch DINING 29 25 30 26 31 27 32 28 33 29 34 30 35 Breakfast / LunchBreakfast BUFFETS 37 28 24 27 23 26 22 25 21 24 20 23 19 22 exhibit hall 40 15 13 16 14 17 15 18 16 19 17 20 18 21 39 INNOVATION 14 12 13 11 12 10 11 9 10 8 9 7 8 EXHIBITORS CHALLENGE 36 38 FINALISTS 1 1 2 2 3 3 4 4 5 5 6 6 7 Partnering Check-in PARTNERING Forum Lunch BUFFETS Breakfast / Breakfast RESTROOM cocktail reception REGISTRATION content Welcome to RESI - - - - - - - - - - - - - - - 2 RESI Agenda - - - - - - - - - - - - - - - - - - 3 BOSTON RESI Innovation Challenge - - - - - - - 5 Exhibiting Companies - - - - - - - - - - 12 Track 1: Therapeutics Investor Panels - - - - - - - - - - - - - - - 19 Track 2: Device, Diagnostic, & HCIT Investor Panels - - - - 29 Track 3: Entrepreneur Workshops - - - - - - - - - - - - - - - - - - 38 Track 4: Asia-North America Workshop & Panels - - - - - - 41 Track 5: Partnering Forum - - - - - - - - - - - - - - - - - - - - - - - - 45 Sponsors & Media Partners - - - - - - - - - - - - - - - - - - - - - - - 46 1 welcome to resi On behalf of Life Science Nation (LSN) and our title sponsors WuXi AppTec and Johnson & Johnson Innovation JLABS, I would like to thank you for joining us at RESI Boston. LSN is very happy to welcome you all to Boston, the city where it all began, for our 14th RESI event.
    [Show full text]
  • Buyouts' List of Candidates to Come Back to Market In
    32 | BUYOUTS | December 3, 2018 www.buyoutsnews.com COVER STORY Buyouts’ list of candidates to come back to market in 2019 Firm Recent Fund Strategy Vintage Target ($ Amount Raised Year Mln) ($ Mln) Advent International Advent International GPE VII, L.P. Large Buyout 2012 $12,000.00 $13,000.00 Advent International Advent Latin American Private Equity Fund VI, L.P. Mid Buyout 2015 $2,100.00 $2,100.00 American Industrial Partners American Industrial Partners Capital Fund VI LP US MM Buyout 2015 N/A $1,800.00 Apollo Global Management Apollo Investment Fund IX Mega Buyout 2017 $23,500.00 $24,700.00 Aquiline Capital Partners Aquiline Financial Services Fund III Mid Buyout 2015 $1,000.00 $1,100.00 Arlington Capital Partners Arlington Capital Partners IV LP Mid Buyout 2016 $575.00 $700.00 Black Diamond Capital Management BDCM Opportunity Fund IV Turnarounds 2015 $1,500.00 $1,500.00 Blackstone Group Blackstone Real Estate Partners VIII LP Global Real Estate Opp 2015 $4,518.11 $4,518.11 Bunker Hill Capital Bunker Hill Capital II Lower mid market buyout 2011 $250.00 $200.00 CCMP Capital CCMP Capital Investors III, L.P. Buyout/Growth Equity 2014 N/A $1,695.65 Centerbridge Partners Centerbridge Capital Partners III Global Dist Debt Control 2014 $5,750.00 N/A Centerbridge Partners Centerbridge Special Credit Partners III Hedge Fund 2016 $1,500.00 N/A Charlesbank Capital Partners Charlesbank Equity Fund IX, L.P. Mid Buyout 2017 $2,750.00 $2,750.00 Craton Equity Partners Craton Equity Investors II, L.P.
    [Show full text]
  • Semi-Annual Market Review
    Semi-Annual Market Review HEALTH IT & HEALTH INFORMATION SERVICES JULY 2019 www.hgp.com TABLE OF CONTENTS 1 Health IT Executive Summary 3 2 Health IT Market Trends 6 3 HIT M&A (Including Buyout) 9 4 Health IT Capital Raises (Non-Buyout) 14 5 Healthcare Capital Markets 15 6 Macroeconomics 19 7 Health IT Headlines 21 8 About Healthcare Growth Partners 24 9 HGP Transaction Experience 25 10 Appendix A – M&A Highlights 28 11 Appendix B – Buyout Highlights 31 12 Appendix C – Investment Highlights 34 Copyright© 2019 Healthcare Growth Partners 2 HEALTH IT EXECUTIVE SUMMARY 1 An Accumulating Backlog of Disciplined Sellers Let’s chat about fireside chats. The term first used to describe a series of evening radio addresses given by U.S. President Franklin D. Roosevelt during the Great Depression and World War II is now investment banker speak for “soft launches” of sell-side and capital raise transactions. Every company has a price, and given a market of healthy valuations, more companies are testing the waters to find out whether they can achieve that price. That process now looks a little more informal, or how you might envision a fireside chat. Price (or valuation) discovery for a company can range from a single conversation with an individual buyer to a full-blown auction with hundreds of buyers and everything in between, including a fireside chat. Given the increasing share of informal conversations, the reality is that more companies are for sale than meets the eye. While the healthy valuations publicized and press-released are encouraging more and more companies to price shop, there is a simultaneous statistical phenomenon in perceived valuations that often goes unmentioned: survivorship bias.
    [Show full text]
  • Mbamission's Insider's Guide
    mbaMission’s Insider’s Guide The Wharton School University of Philadelphia Philadelphia, PA 2019–2020 presented by Applying to Business School? mbaMission is your partner in the process! Our team of dedicated, full-time admissions experts has helped thousands of applicants get into their dream MBA programs. These skilled storytellers and MBA graduates will work one-on-one with you to help you discover, select, and articulate your unique stories and stand out from the crowd. Why mbaMission? 15+ years of experience advising Ranked number one firm by GMAT tens of thousands of business Club and Poets&Quants school applicants Exclusively recommended by Extensive, unparalleled library of Services available for all stages of Manhattan Prep since 2009 supplementary content the application process Schedule a free, 30-minute consultation at www.mbamission.com/consult, and start getting answers to all your MBA admissions questions! +1-646-485-8844 [email protected] www.mbamission.com About mbaMission With our collaborative, full-time team of experienced advisors, mbaMission has elevated and professionalized the world of MBA admissions consulting, earning the exclusive recommendation of the world’s leading GMAT prep firms, Manhattan Prep and Kaplan GMAT, and hundreds more verified five-star reviews on GMAT Club than any other such firm. mbaMission prides itself on its high-touch client engagement model and robust library of free content that includes these Insider’s Guides as well as our Complete Start-to-Finish MBA Admissions Guide. Having already helped thousands of aspiring MBAs from around the world gain entry into elite US and international business schools, mbaMission continues to grow and improve in our quest to “graduate” additional classes of satisfied clients.
    [Show full text]
  • Investor Relations Marketing & Communications Forum
    Investor Relations Marketing & Communications Forum Virtual experience 2020 September 2-3 | Available anywhere The largest global event for PE Investor Relations, Marketing & Communications A new virtual experience Customize your agenda Available anywhere Industry leading IR and Mix and match 3 think tank Enjoy the Forum from the marketing content selections, 3 interactive comfort of your home office and The Forum’s in-depth sessions are discussion rooms, 12 breakouts on-demand access for up to 12 designed to help you formulate and panel sessions to your liking months after the event is over effective plans and develop crucial for a personalize event strategies to attract investors experience A new kind of networking Built-in calendar and Networking lounges Gain early access to the attendee automated reminders Explore and meet with industry list and start scheduling 1-to-1 Easily download and sync your service providers to discover the or small group meetings or direct event agenda with preferred latest trends and technologies message fellow attendees in tracks and 1-to-1 meetings to your advance own work calendar Speakers include Marilyn Adler Nicole Adrien Christine Anderson Mary Armstrong Michael Bane Managing Partner Chief Product Officer Senior Managing Senior Vice President, Head of US Investor Mizzen Capital and Global Head of Director, Global Head Global Head of Relations Client Relations of Public Affairs & Marketing and Ardian Oaktree Capital Marketing Communications Blackstone General Atlantic Devin Banerjee Charles Bauer Gina
    [Show full text]
  • Public Investment Memorandum Searchlight Capital II, L.P. Private
    COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLOYEES’ RETIREMENT SYSTEM Public Investment Memorandum Searchlight Capital II, L.P. Private Debt Commitment James F. Del Gaudio Senior Investment Professional September 22, 2015 COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLOYEES’ RETIREMENT SYSTEM Recommendation: Staff, together with Portfolio Advisors, recommends to the Board a commitment of up to $100 million to Searchlight Capital II, L.P. (“Fund II” or the “Fund”). Searchlight Capital Partners, L.P. (“Searchlight” or the “Firm”) is sponsoring the Fund to make value oriented investments in private equity and distressed situations across North America and Europe. Firm Overview: Searchlight was founded in 2010 by Oliver Haarmann, Erol Uzumeri and Eric Zinterhofer (collectively, the "Founding Partners"). At that time, Searchlight established three offices, one in each of New York, London and Toronto. Searchlight completed the final closing of its first fund, Searchlight Capital, L.P. (“Fund I”) in March 2012, with $864 million of committed capital. The Firm has 31 employees; including 18 investment professionals and seven finance, legal and investor relations professionals. The Founding Partners of Searchlight have invested over $6.6 billion during their careers and have over 60 years of collective experience. Prior to co-founding Searchlight, Oliver Haarmann was a senior partner of KKR in London, Erol Uzumeri was the head of Private Equity for the Ontario Teachers’ Pension Plan in Toronto and Eric Zinterhofer was a senior partner at Apollo in New York. Investment Strategy: Searchlight employs a value-oriented investment philosophy which seeks to deliver strong performance across economic cycles. The Fund will pursue private equity and distressed investments in leading North American and European businesses.
    [Show full text]
  • Supplementary Data Supplementary Data 1
    Building Long-term Wealth by Investing in Private Companies Annual Report and Accounts 12 Months to 31 January 2021 Supplementary Data Supplementary Data 1 HVPE’s HarbourVest Fund Investments at 31 January 2021 HVPE’s HarbourVest Fund investments and secondary co-investments are profiled below. Financial information at 31 January 2021 for each fund is provided in the Financial Statements of the Company’s Annual Report and Accounts on pages 79 to 82. V = Venture, B = Buyout, O = Other, P = Primary, S = Secondary, D = Direct Co-investment HarbourVest Fund Phase Vintage Year Stage Geography Strategy Investment Phase HIPEP IX Partnership Fund Investment 2020 V, B EUR, AP, RoW P, S, D Secondary Overflow Fund IV Investment 2020 V, B Global S 2020 Global Fund Investment 2020 V, B, O Global P, S, D HarbourVest Real Assets IV Investment 2019 O Global S HarbourVest Credit Opportunities Fund II Investment 2019 O US D Dover Street X Investment 2019 V, B Global S HarbourVest 2019 Global Fund Investment 2019 V, B, O Global P, S, D HarbourVest Partners Co-Investment V Investment 2018 V, B, O Global D HarbourVest Adelaide Investment 2018 O US, EUR, RoW S, D HarbourVest 2018 Global Fund Investment 2018 V, B, O Global P, S, D HarbourVest Partners XI Venture Investment 2018 V US P, S, D HarbourVest Partners XI Micro Buyout Investment 2018 B US P, S, D HarbourVest Partners XI Buyout Investment 2018 B US P, S, D HIPEP VIII Asia Pacific Fund Investment 2017 V, B AP P, S, D HarbourVest 2017 Global Fund Investment 2017 V, B, O Global P, S, D HIPEP VIII Partnership
    [Show full text]
  • ILPA Releases Second Report in Diversity in Action Series
    ILPA Releases Second Report in Diversity in Action Series Diversity in Action – Sharing Our Progress Report Details the Initiative’s Growth and Insights Into Integrating DEI Into Investment Strategies 1776 Eye St. NW August 31, 2021 (Washington, D.C.) The Institutional Limited Partners Association (ILPA) today released the Suite 525 second report in its Diversity in Action – Sharing Our Progress series. The report series is an extension of ILPA’s Washington, DC Diversity in Action initiative and aims to provide actionable recommendations on steps that can be taken to 20006 improve diversity, equity and inclusion in private markets. “The industry continues to respond positively to the Diversity in Action Initiative with new signatories joining every week,” said Steve Nelson, CEO of ILPA. “The Initiative now claims 180 signatories who have all been incredibly active in conversations with one another and have acted as tremendous partners to ILPA on our related work, having meaningfully contributed to our updated ILPA Diversity Metrics Template.” The Diversity in Action – Sharing Our Progress report series tracks the evolution of Initiative signatories by geography, strategy and fund size as well as progress on adoption of all the actions within the Framework. As of August 2021, the Initiative’s geographic reach is increasing, now with 38 signatories outside North America, a 52% increase in this cohort since April. The latest report focuses on how signatories are integrating diversity, equity and inclusion into investment strategies including
    [Show full text]
  • The View Beyond Venture Capital
    BUILDING A BUSINESS The view beyond venture capital Dennis Ford & Barbara Nelsen Fundraising is an integral part of almost every young biotech’s business strategy, yet many entrepreneurs do not have a systematic approach for identifying and prioritizing potential investors—many of whom work outside of traditional venture capital. re you a researcher looking to start a Why and how did the funding landscape During the downturns, it quickly became Anew venture around a discovery made change? apparent that entrusting capital to third-party in your laboratory? Perhaps you have already The big changes in the life science investor alternative fund managers was no longer an raised some seed money from your friends landscape start with the venture capitalist effective strategy, and investors began to with- and family and are now seeking funds to sus- (VC). In the past, venture capital funds were draw capital. The main reason for the with- tain and expand your startup. In the past, the typically capitalized by large institutional drawal (especially from VCs in the early-stage next step on your road to commercialization investors that consisted of pensions, endow- life science space) was generally meager returns would doubtless have been to seek funding ments, foundations and large family offices across the asset class; despite the high risk and from angels and venture capital funds; today, with $100 million to $1 billion in capital long lockup periods that investors accepted in however, the environment for financing an under management. Traditionally, the major- return for a promise of premium performance, early-stage life science venture looks strik- ity of these institutions maintained a low-risk, VCs were often not returning any more capital ingly different from that familiar landscape low-return portfolio of stocks and bonds that than investors would have earned by making of past decades.
    [Show full text]
  • Investment Vendors
    INVESTMENT VENDORS The following is a listing of the investment managers, custodians, and consultants that serve the Massachusetts public pension systems. The listing is based on information supplied by the retirement boards. Retirement Investment Vendors Board Adams • PRIT Amesbury • PRIT Andover • PRIT • RhumbLine Advisers Consultant: Dahab Associates Arlington • PRIT Custodian: People’s United Bank Attleboro • Amalgated Bank • Hancock Timber Resource Group, Inc. • PRIT Custodian: People’s United Bank • BTG Pactual Timberland Investment Group • Intercontinental Real Estate Corp. • RhumbLine Advisers Consultant: Dahab Associates Inc. • Copeland Capital Management • Invesco Core Real Estate USA, LP • State Street Global Advisors • Fidelity Institutional Asset Management • Invesco National Trust Company • Van Eck • Frontier Capital Management Co., LLC • Peregrine Capital Barnstable County • PRIT Belmont • AEW Capital Management, LP • HarbourVest Partners, LLC • PRIT Custodian: People’s United Bank • Atlanta Capital • Loomis, Sayles & Company • RhumbLine Advisers Consultant: NEPC, LLC • Carillion Tower Advisors • Pacific Investment Management Company, LLC • Rothschild Asset Management Inc. Berkshire County • PRIT Beverly • PRIT Blue Hills Regional • PRIT Boston (City) • 57 Stars, LLC • EnTrust Global Partners • Polunin Capital Partners • AEW Capital Management, LP • Goldentree Asset Management, LP • Prudential Capital Partners Custodian: State Street Bank & Trust • Alcentra NY, LLC • Grosvenor Capital Management, LP • Prudential
    [Show full text]